COMPUTATIONAL BIOLOGY - NATURAL LANGUAGE PROCESSING - MACHINE LEARNING
Network Immunopharmacology Interactome
Maximise ROI in Monotherapy Programs
Vertically Integrated End-2-End Workflow
The integrated network pharmacology platform has particular advantages for complex immuno/inflammation-based diseases. It works by generating obvious and non-obvious knowledge on the immuno/inflammation interactome, diseases and drug targets from structured and unstructured data. This is achieved using proprietary natural language processing, machine learning and feature engineering algorithms which integrate data from public and private sources. BioXplor leverages it's network pharmacology platform to prioritize optimal multi-therapeutic/multi-target strategies, novel indications, and clinical responders and non-responders, based on safety and efficacy evidence. The platform has been optimized and successfully validated with top tier clients including Novartis, Bayer and Merck, for Biomarker ID and Clinical Responder ID, Drug Combinations, Indication Expansion, Drug Repositioning, Target and Multi-Target ID, Pathway Analysis and DNA/RNA Sequencing Data Interpretation.
BioXplor delivers high-quality and rapid-turnaround contract research services from data-driven discovery to wet lab validation for clinical responder ID, indication expansion and drug combinations. The detailed recommendation report can be purely data-driven using BioXplor's proprietary knowledge discovery platform only, or integrate client data for additional analysis. Via our trusted external partner network, the workflow can be extended to generate and integrate new data from single-cell sequencing analysis, cell-based assays and preclinical animal model studies.
For co-development partnerships we form joint ventures together with select academic and biotech teams to combine domain, target and/or platform synergies to rapidly develop programs from hypotheses to validation at a fraction of the time and cost of traditional approaches. BioXplor is actively engaged in programs in inflammation, autoimmunity and immuno-oncology.
Contract Research & Drug Discovery Partnerships
BioXplor was founded in January 2017 and is backed by the European Union (EIC/Horizon 2020, EIT Health), UC Berkeley Skydeck, Creative Destruction Labs and Merck accelerators, amongst other partners. The team has combined unique expertise in bioinformatics/computer science, immunology/inflammation and drug discovery/clinical trials, which are the core components of what we do. We are passionate about applying data-driven approaches to accelerate novel discoveries in complex immunology/inflammation-based diseases.